BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...is going after the adaptor molecule ASC. ZyVersa licensed an anti-ASC mAb, IC 100, from InflamaCORE LLC...
BioCentury | Apr 22, 2019
Company News

Variant expands pipeline with InflamaCore inflammasome deal

...preclinical testing for multiple sclerosis. In a 2018 paper published in Frontiers in Neurology , InflamaCore LLC...
...CARD domain containing Chris Lieu, Staff Writer Variant Pharmaceuticals Inc. PYD and CARD domain containing (PYCARD) (ASC) Multiple sclerosis (MS) InflamaCore LLC...
Items per page:
1 - 2 of 2
BioCentury | Aug 16, 2019
Targets & Mechanisms

Biotechs explore the next generation of inflammasome targets, with caution

...is going after the adaptor molecule ASC. ZyVersa licensed an anti-ASC mAb, IC 100, from InflamaCORE LLC...
BioCentury | Apr 22, 2019
Company News

Variant expands pipeline with InflamaCore inflammasome deal

...preclinical testing for multiple sclerosis. In a 2018 paper published in Frontiers in Neurology , InflamaCore LLC...
...CARD domain containing Chris Lieu, Staff Writer Variant Pharmaceuticals Inc. PYD and CARD domain containing (PYCARD) (ASC) Multiple sclerosis (MS) InflamaCore LLC...
Items per page:
1 - 2 of 2